What Changes During Perimenopause and Why It Affects the Skin
Perimenopause typically begins in the mid-forties, though it can start earlier, and the hormonal shifts involved have consequences that extend well beyond the most discussed symptoms. Oestrogen decline affects skin function in ways that are distinct from the gradual ageing process and require a different formulation approach than conventional anti-ageing products provide.
Oestrogen plays a direct role in several skin processes. It stimulates fibroblasts to produce collagen and hyaluronic acid. It supports the barrier function of the epidermis through its influence on ceramide synthesis. It regulates sebum production. It contributes to wound healing speed. When oestrogen levels decline, each of these functions is affected simultaneously, which is why perimenopausal skin changes can appear quite rapidly and affect multiple aspects of skin condition at once.
The loss of collagen accelerates. Studies suggest that women can lose up to 30 percent of their skin collagen in the first five years following the onset of menopause. The skin becomes thinner, less resilient and less able to retain moisture. Fine lines that were gradual in their development over decades can deepen visibly in a relatively short period. The skin may also become more sensitive during this transition, partly because barrier integrity is compromised and partly because increased skin thinning reduces the buffer between environmental stressors and responsive deeper layers.
The Inadequacy of Generic Anti-Ageing Formulations
Most anti-ageing skincare is formulated with a generalised approach to skin ageing that does not distinguish between intrinsic ageing, photo-ageing and hormonally driven skin changes. Products targeting fine lines, dullness and uneven tone often use the same actives at the same concentrations regardless of the underlying mechanism driving those changes in a particular person at a particular life stage.
For perimenopausal skin, this generic approach fails in several ways. First, the volume of change occurring simultaneously requires a multi-correctional rather than single-concern approach. Addressing fine lines while ignoring barrier loss, or targeting tone while neglecting hydration, produces partial results at best. Second, the speed of change means that products requiring months of consistent use to demonstrate efficacy may not keep pace with the progression of skin changes if they are addressing only one concern. Third, skin sensitivity during this transition means that high-dose actives in irritating formats may cause more disruption than benefit.
The requirement is for a formulation that delivers multiple clinically dosed actives simultaneously, in a delivery system that makes high-dose use possible without irritation, within a structure that also supports the barrier function that oestrogen decline compromises.
Vitamin A, B3 and C in a Perimenopausal Context
The three most research-supported topical actives for the specific concerns of perimenopausal skin are vitamin A derivatives, vitamin B3 and vitamin C. Each addresses a distinct mechanism of the hormonal skin ageing process.
Vitamin A in the retinaldehyde form stimulates fibroblast activity and increases collagen synthesis. At 1% encapsulated concentration with slow release across 8 to 12 hours, it provides a dose that can sustain the collagen-stimulating signal needed to counteract accelerated collagen loss, in a format that is well tolerated twice daily even by skin that has become more reactive during the perimenopausal transition.
Vitamin B3 at 10% encapsulated concentration addresses the melanin transfer that leads to the uneven tone and new pigmentation that frequently appears during this period. Post-inflammatory hyperpigmentation becomes more pronounced as skin recovery slows. Hormonal fluctuations can trigger melasma-type pigmentation changes that did not occur in earlier decades. Regular use of 10% vitamin B3 interrupts the melanin pathway at the transfer stage, gradually reducing existing discolouration and limiting new deposition.
When both are combined in an encapsulated delivery system within a single formula, the approach begins to match the multi-mechanism nature of perimenopausal skin change. Professional-grade skincare from Rejuvaus uses this combination within the i·Active™ protocol, specifically suited to this life stage because the formulation architecture addresses multiple simultaneous concerns rather than requiring separate products for each.
Barrier Support as a Non-Negotiable Requirement
Barrier restoration is not an optional add-on for perimenopausal skin. It is foundational to every other benefit a skincare routine can deliver. Without adequate barrier function, moisture loss accelerates, sensitivity increases and the controlled delivery of actives is compromised because the structural environment they need to work within is destabilised.
Oestrogen contributes to ceramide synthesis in the skin. As levels decline, ceramide production falls and the barrier loses its ability to maintain the tight junctions that prevent water loss and exclude irritants. This is why perimenopausal skin often feels tight, dry or reactive even in women who had no such issues in earlier decades.
Professional-grade formulations that include a skin-identical lipid barrier complex, pre and postbiotic ferments, and dual-weight hyaluronic acid address barrier restoration as a primary function rather than a secondary hydration benefit. The 0.25% lemongrass sole preservative approach is relevant here as well: a formulation that keeps its preservative burden minimal reduces the chemical disruption to barrier-sensitive perimenopausal skin while still maintaining product safety.
Building a Routine for This Life Stage
The simplest effective routine for perimenopausal skin is typically a twice-daily serum combining the actives described above, applied to cleansed skin before a moisturiser and, in the morning, an SPF. The routine needs to be consistent over at least eight to twelve weeks before the cumulative benefit of active stimulation becomes clearly visible.
Adding a second serum with 15% encapsulated pore-clearing BHA addresses the texture and congestion changes that hormonal fluctuations can cause. Some women find that adult-onset breakouts or increased congestion accompany the perimenopausal period even without a history of acne. The pore-clearing BHA at an encapsulated clinical dose addresses this without stripping the barrier that oestrogen decline has already compromised.
The goal is a routine that can be maintained consistently, twice daily, through a skin transition that may last years. Professional-grade formulations designed with this sustained-use context in mind, with the tolerability to match, are the appropriate tool for the job.
